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Abstract
Dementia with Lewy bodies (DLB) and Parkinson’s Disease (PD) are neurodegenerative disorders of the aging population
characterized by the abnormal accumulation of alpha-synuclein (alpha-syn). Previous studies have suggested that
excitotoxicity may contribute to neurodegeneration in these disorders, however the underlying mechanisms and their
relationship to alpha-syn remain unclear. For this study we proposed that accumulation of alpha-syn might result in
alterations in metabotropic glutamate receptors (mGluR), particularly mGluR5 which has been linked to deficits in murine
models of PD. In this context, levels of mGluR5 were analyzed in the brains of PD and DLB human cases and alpha-syn
transgenic (tg) mice and compared to age-matched, unimpaired controls, we report a 40% increase in the levels of mGluR5
and beta-arrestin immunoreactivity in the frontal cortex, hippocampus and putamen in DLB cases and in the putamen in PD
cases. In the hippocampus, mGluR5 was more abundant in the CA3 region and co-localized with alpha-syn aggregates.
Similarly, in the hippocampus and basal ganglia of alpha-syn tg mice, levels of mGluR5 were increased and mGluR5 and
alpha-syn were co-localized and co-immunoprecipated, suggesting that alpha-syn interferes with mGluR5 trafficking. The
increased levels of mGluR5 were accompanied by a concomitant increase in the activation of downstream signaling
components including ERK, Elk-1 and CREB. Consistent with the increased accumulation of alpha-syn and alterations in
mGluR5 in cognitive- and motor-associated brain regions, these mice displayed impaired performance in the water maze
and pole test, these behavioral alterations were reversed with the mGluR5 antagonist, MPEP. Taken together the results
from study suggest that mGluR5 may directly interact with alpha-syn resulting in its over activation and that this over
activation may contribute to excitotoxic cell death in select neuronal regions. These results highlight the therapeutic
importance of mGluR5 antagonists in alpha-synucleinopathies.
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Introduction
Movement disorders with parkinsonism and cognitive impair-
ment continue to be a significant neurological problem in the
aging population. While patients with classical Parkinson’s Disease
(PD) present with tremor, motor deficits and autonomic
dysfunction(s), others patients develop cognitive alterations
including dementia. Patients that present first with cognitive
impairments followed by development of parkinsonism are
denominated dementia with Lewy bodies (DLB) to distinguish
them from patients with PD dementia (PDD). Jointly this
heterogeneous group of disorders is referred to as Lewy body
disease (LBD) [1]. These conditions are associated with progressive
and selective loss of dopaminergic and non-dopaminergic cells [2]
and the formation of Lewy bodies (LBs) and Lewy neurites
containing fibrillar alpha-synuclein (alpha-syn) [3,4,5,6,7,8] in
cortical and subcortical regions [9,10,11]. Previous studies have
suggested that excitotoxicity may contribute to neurodegeneration
in these disorders however the underlying mechanisms and their
relationship to alpha-syn remain unclear.
Synucleins are a family of related proteins including alpha-,
beta-, and gamma-synuclein. Alpha-syn is a 14 kDa ’naturally
unfolded protein’ [12,13] abundant at the presynaptic terminal
[14] and likely plays a role in modulating vesicular synaptic release
[15]. Abnormal accumulation of alpha-syn is thought to be
centrally involved in the pathogenesis of both sporadic and
inherited forms of parkinsonism as mutations and multiplications
in the alpha-syn gene have been associated with rare familial forms
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transgenic (tg) mice [17,18,19] and Drosophila [20] recreates several
pathological and dysfunctional motor performance features of PD.
Recent studies have shown that accumulation of oligomeric, rather
than polymeric (fibrilar) forms of alpha-syn in the synapses and
axons may be responsible for neuronal dysfunction and degener-
ation [21,22,23].
In addition to the modulation of vesicular synaptic release,
alpha-syn has been shown to regulate dopaminergic neurotrans-
mission (reviewed by [24]) and to be involved in dopamine release
[25,26] whilst dopamine in turn, has been reported to promote
alpha-syn oligomerization [27,28]. These interactions between
dopamine and alpha-syn may help explain the selective vulner-
ability of the dopaminergic system in PD. Recent studies have
demonstrated that, in addition to well-documented dopaminergic
alterations, other neurotransmitter systems are also dysregulated in
PD and DLB. For example, altered glutamatergic neurotransmis-
sion within basal ganglia circuitry is thought to contribute to the
clinical presentation of parkinsonian-related motor symptoms,
though the mechanisms underlying this are not yet fully
understood. Abnormal activation of group I metabotropic
receptors (mGluR1 and mGluR5) within the basal ganglia
circuitry has been proposed to account for cognitive and motor
alterations in patients with DLB [29,30,31]. mGluR5 in particular
has attracted considerable interest because of its potential
involvement in Alzheimer’s Disease (AD) [32] and PD [33,34],
its role in learning and memory [35,36], and its abundant
expression in the frontal cortex, limbic system, and caudoputamen
[37]—brain regions selectively affected in AD and PD.
Further support for a role of group I mGluR receptors in the
pathogenesis of PD and DLB steams from studies showing that
mGluR5 antagonists ameliorate the behavioral alterations in
animal model of parkinsonism [38,39,40,41] and are neuropro-
tective against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine) neurotoxicity in animals [42,43]. Mice lacking the mGluR5
receptors also display reduced MPTP toxicity [43].
Although extensive behavioral pharmacology studies with
mGluR5 antagonists in PD-like animal models have been
performed, surprisingly very limited information is available as
to the potential role of alterations in mGluR’s in the pathogenesis
of the excitotoxicity in PD or DLB patients, or alpha-syn tg animal
models. Here we describe studies of mGluR5 expression the brains
of patients with DLB or PD and in alpha-syn over-expressing tg
mice, and discuss a role for altered mGluR5 expression in
excitotoxicity. Furthermore, we present evidence that mGluR5
receptor antagonism is capable of ameliorating the behavioral
deficits observed in alpha-syn tg mice. Taken together these results
support the notion that mGluRs play an important role in the
pathogenesis of disorders with alpha-syn accumulation and that
mGluR5 receptors may be an important target for therapeutic
intervention.
Materials and Methods
Human specimens, Neuropathological Evaluation and
Criteria for diagnosis
A total of 24 cases (n=8 non-demented controls; n=8 DLB and
n=8 PD cases) were included for the present study. Autopsy
material was obtained from patients (Table 1) studied neurolog-
ically and psychometrically at the Alzheimer Disease Research
Center/University of California, San Diego (ADRC/UCSD). The
last neurobehavioral evaluation was performed within 12 months
before death and included Blessed score, Mini Mental State
Examination (MMSE) and dementia-rating scale (DRS) [44,45].
Brains were processed and evaluated according to standard
methods [46]. At autopsy, brains were divided sagitally, the left
hemibrain was fixed in formalin of 4% paraformaldehyde (PFA)
for neuropathological analysis and the right frozen at 270uC for
subsequent neurochemical analysis. Paraffin sections from 10%
buffered formalin-fixed neocortical, limbic system and subcortical
material stained with hematoxylin and eosin (H&E), thioflavine-S,
ubiquitin (Dako, Carpinteria, CA) and a-syn (Millipore, Teme-
cula, CA) were used for routine neuropathological analysis that
included assessment of plaques, tangles, Lewy bodies and Braak
stage [46]. The diagnosis of DLB was based in the initial clinical
presentation with dementia followed by parkinsonism and the
presence of alpha-syn and ubiquitin-positive LBs in cortical and
subcortical regions [47,48]. The diagnosis of PD was based on the
initial presentation with parkinsonism and presence of alpha-syn
and ubiquitin positive LBs in subcortical regions.
Transgenic mouse lines
Transgenic mice over expressing wildtype human (h) alpha-syn
under the control of the platelet-derived growth factor (PDGF) (D-
line; [19]) and the mThy1 (line 61; [49]) promoters were used. The
PDGF-alpha-syn tg mice were selected because they display
accumulation of a-syn in the frontal cortex and limbic system
similar to DLB accompanied by behavioral deficits, early motor
alterations, loss of dopaminergic terminals and formation of
inclusion bodies [19]. The mThy1-alpha-syn tg mice were selected
because they display more extensive a-syn accumulation in the
frontal cortex, limbic system and subcortical regions including the
basal ganglia and the substantia nigra. For the immunoblot and
immunochemical studies a total of 24 mice were used (n=8 non-
tg; n=8 PDGF-alpha-syn and n=8 mThy1-alpha-syn tg) age 6
months old. For the behavioral and therapeutic studies a total of
36 animals were utilized (n=12 non-tg; n=12 PDGF-alpha-syn
and n=12 mThy1-alpha-syn tg) at 9 months of age. From each of
the groups half of the mice (n=6) were treated with vehicle only
and the other half (n=6) were treated with MPEP (2-Methyl-6-
(phenylethynyl)-pyridine).
Treatment with mGluR5 antagonist and Behavioral
testing
For these experiments MPEP, a selective and systemically active
mGluR5 receptor antagonist, was used to test the effects of
mGluR5 receptor antagonism on behavioral performance [50].
MPEP HCl was obtained from Tocris Biosciences (Ellisville, MO;
Catalog #1212), and dissolved in 0.9% saline solution at a dose of
20 mg/ml. This dose was chosen based on reports in the literature
demonstrating effective dose ranges for behavioral studies in mice
without adverse effects [51,52]. The MPEP solution was sonicated
to ensure complete dilution and the solution was used the same
day. MPEP was administered by intraperitoneal (IP) injection, the
animals were weighed on the day of testing and the appropriate
volume was determined and recorded for each animal (approx-
imately 0.2 ml/animal). A 30-minute pre-injection time was used,
and administration times were staggered to account for this time
prior to testing. The behavioral effects of MPEP in the a-syn over-
expressing tg mice were tested in the vertical pole test (motor test)
and the Morris water maze (learning and memory test).
The pole test was divided into 3 phases, including a pretest (with
saline injection), a challenge with MPEP administration, and a
reassessment (no injections) to determine performance one week
after MPEP administration. The percentage change in perfor-
mance from Test 1 to Test 2 was determined by calculating the
difference between success ratios on these two separate test days.
Animals underwent testing on a vertical pole apparatus to evaluate
mGluR5 in A-Synucleinopathy
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e14020their ability to negotiate and descend the apparatus. The testing
procedures were derived from previous reports [53,54]. The
apparatus consists of a rough-surfaced pole (diameter 1 cm; height
50 cm) inserted perpendicular to a circular platform. The pole was
lightly roughened with medium grade sandpaper in between
animals to ensure that all animals were presented with a
comparable pole surface. The circular platform was covered with
multilayered padding to avoid injury to the animals in the event of
a fall from the apparatus. The top padded surface was disposable
and frequently changed to avoid a soiled surface. Non-tg mice
easily complete this task, and to date, our group has noted
performance deficits in the alpha-syn tg mice as early as 4 months
of age. The pole testing session consisted of 2 training trials
followed by 5 test trials (7 trials total). The first 2 untimed trials
served to acquaint the animal with the apparatus. The 5 test trials
were timed to a maximum of 120 sec. Two timed measures were
recorded including: (1) the time until the animal completely turned
around and re-oriented towards platform base (T-Turn), and (2)
the total time spent on apparatus (T-Total). This procedure was
repeated a total of 5 times. The ratio of success for each subject
based on the number of times (out of 5 total trials) the apparatus
was successfully negotiated was noted.
To evaluate the effects of MPEP on learning and memory in the
alpha-syn over-expressing tg mice they were tested in the Morris
water maze as previously described [55]. Mice were treated for 28
days with saline vehicle solution of MPEP as a daily IP injection
(20 mg/ml, 0.2 ml per animal per day). At day 20 of the
treatments mice were tested in the water maze for 8 days. For this
purpose a pool (diameter 180 cm) was filled with opaque water
(24uC) and mice were first trained to locate a visible platform (days
1–3) and then a submerged hidden platform (days 4–7) in three
daily trials 2–3 min apart. Mice that failed to find the hidden
platform within 90 seconds were placed on it for 30 seconds. The
same platform location was used for all sessions and all mice. The
starting point at which each mouse was placed into the water was
changed randomly between two alternative entry points located at
a similar distance from the platform. On day 7, another visible
platform trial was performed to exclude differences in motivation
and fatigue. On day 8 the platform was removed (probe test) and
mice were tested to evaluate the numbers of entrances and time
expended in the target quadrant. Time to reach the platform
(latency), path length, and swim speed were recorded with a
Noldus Instruments EthoVision video tracking system (San Diego
Instruments, San Diego, CA) set to analyze two samples per
second. UCSD is an Institutional Animal Care and Use
Committee accredited institution and the UCSD Animal Subjects
Committee approved the experimental protocol followed in all
studies according to the Association for Assessment and Accred-
itation of Laboratory Animal Care International guidelines.
Immunoblot analysis
The immunoblot procedures for human and transgenic mouse
samples were performed as previously described [19]. Briefly,
dissected frozen tissues were homogenized, and processed and
separated into cytosolic and particulate fractions. The nuclear
fraction was obtained by resuspending the pellet (from the
5000 g spin after homogenization) in buffer +1%SDS +1%
TritonX. Incubated on ice for 15 minutes, vortexing every 3
minutes, then centrifuged for 10 minutes at 14,000 g at 4uC.
The protein concentrations of individual samples were deter-
mined using a BCA protein assay kit (Pierce Biotechnology,
Rockford, IL). Approximately 20 ug of each fraction were
loaded onto either 3–8% Tris-acetate (mGluR5 human) or 4–
12% Bis-Tris (all others) SDS polyacrylamide gel electrophoresis
(SDS/PAGE) gels (Invitrogen, Carlsbad, CA), transferred into
Immobilon membranes (Millipore, Temecula, CA), blocked with
either 3% BSA (for animal samples) or 5% Milk/1% BSA (for
human samples) in PBS, and incubated overnight at 4uCw i t h
antibodies against mGluR5 (rabbit polyclonal, 1:1000, Milli-
pore, Temecula, CA), beta-arrestin (rabbit polyclonal, 1:1000,
Cell Signaling, Boston, MA), extracellular signal-regulated
kinase (ERK, mouse monoclonal, 1:1000, Cell Signaling,
Boston, MA), phospho-ERK (pERK, mouse monoclonal,
1:1000 Cell Signaling, Boston, MA), Elk-1 member of ETS
oncogene family (Elk-1, rabbit polyclonal, 1:1000, Cell Signal-
ing, Boston, MA, phospho-Elk-1 (pElk-1, rabbit polyclonal,
1:1000, Cell Signalling, Boston, MA), cAMP response element-
binding (CREB, mouse monoclonal, 1:1000 Cell Signaling,
Boston, MA) and phospho-CREB (pCREB, rabbit polyclonal,
1:1000 Cell Signaling, Boston, MA). The next day, blots were
rinsed several times and incubated with the appropriate
secondary antibody on a shaker for 1 hour at room temperature.
Membranes were processed using a chemiluminescence kit
(Western Lightning Chemiluminescence Reagent Plus; Perkin
Elmer, Boston, MA) and imaged using a Versadoc system
(Biorad, Hercules, CA). Following imaging, the membranes were
processed for further immunolabeling using an antibody re-
probing kit (Chemicon, Temecula, CA). Actin loads (Beta-actin,
mouse monoclonal, Sigma, St. Louis, MO) were then deter-
mined for each membrane as a control for protein loading. All
mGluR5 protein levels were normalized using the actin
immunoreactivity values. The Quality One
TM image analysis
program (Biorad, Hercules, CA) was used for quantitative
assessment of bands. Statistical analyses were performed using
one-way ANOVAs and the level for significance set at p,0.05.
Resultant data were graphed using SigmaPlot 9.0 (Systat
Software Inc., Richmond, CA). Graphed data are presented as
the mean optical density (group means mGluR5/actin immu-
nolevels) 6 the standard error of the mean (SEM).
Table 1. Summary of clinical neurobehavioral and post-mortem features for human samples.
Group N
Age
(years,
mean ± SEM)
Gender
M/F
PMT
(hours,
mean ± SEM)
Braak
stage
Blessed score
(mean ± SEM)
Brain weight
(grams,
mean ± SEM)
LBs
neocortex
(score)
LBs midbrain
(score)
Control 8 76 (610) 2/3 8 (63) 0 0 1200 (697) 0 0
Dementia with Lewy
bodies
88 3 ( 65) 4/1 9 (62) III-IV 28 (63) 1216 (685) 3+ 2+
Parkinson’s Disease 8 77 (68) 3/2 6 (62) 0 5 (62) 1276 (6128) 0 3+
LBs= Lewy bodies; PMT= postmortem time, SEM = standard error of the mean.
doi:10.1371/journal.pone.0014020.t001
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laser scanning confocal microsocopy
Briefly, as previously described [56], free-floating 40 mm thick
vibratome sections were washed with Tris buffered saline (TBS,
pH 7.4), pre-treated in 3% H2O2, and blocked with 10% serum
(Vector Laboratories, Burlingame, CA), 3% bovine serum
albumin (Sigma), and 0.2% gelatin in TBS-Tween (TBS-T). For
human brains, sections from the frontal cortex, hippocampus and
putamen were used; for the mice sagittal sections from the
complete brain were studied. Sections were incubated at 4uC
overnight with the monoclonal antibodies against mGluR5
(Millipore) and beta-arrestin (Cell Signaling) or the polyclonal
antibody against a-syn (Millipore). Sectionswere then incubated in
secondary antibody (1:75, Vector), followed by Avidin D
horseradish peroxidase (HRP, ABC Elite, Vector) and reacted
with diaminobenzidine (DAB, 0.2 mg/ml) in 50 mM Tris
(pH 7.4) with 0.001% H2O2. Control experiments consisted of
incubation with pre-immune rabbit serum. To investigate the
effects of postmortem delay and fixation on the levels of mGluR5
immunoreactivity, preliminary studies were performed in a subset
of cases (n=5) with postmortem delay ranging from 4–48 h.
Immunostained sections were imaged with a digital Olympus
microscope and assessment of levels of mGluR5 and arrestin
immunoreactivity was performed utilizing the Image-Pro Plus
program (Media Cybernetics, Silver Spring, MD). For each case a
total of three sections (10 digital images per section at 400x) were
analyzed in order to estimate the average number of immunola-
beled cells per unit area (mm
2) and the average intensity of the
immunostaining (corrected optical density).
Double-immunocytochemical analyses was performed utilizing
the Tyramide Signal Amplification
TM-Direct (Red) system (NEN
Life Sciences, Boston, MA) to detect alpha-syn. Specificity of this
system was tested by deleting each primary antibody. For this
purpose, sections were double-labeled with the monoclonal
antibodies against alpha-syn (1:20,000, Millipore) detected with
Tyramide Red, and mGluR5 detected with fluorescein isothiocy-
anate (FITC)-conjugated secondary antibodies (1:75, Vector). All
sections were processed simultaneously under the same conditions
and experiments were performed twice for reproducibility.
Sections were imaged with laser scanning confocal microscope
BioRad Radiance 2000 (Hercules, CA) equipped with a Nikon
E600FN Ellipse microscope (Japan) and using a Nikon Plan Apo
60x oil objective (NA 1.4; oil immersion).
Tissue section acquisition and immunocytochemistry for
large scale mosaic
An additional group of non-tg and PDGF- alpha-syn tg mice
(n=6 per group; 6 month old) were deeply anesthetized with
Nembutal
TM (pentobarbital) and perfused via intracardiac cath-
eterization. Perfusion with oxygenated Ringer’s solution contain-
ing 250 U/ml heparin, 0.2 mg/ml xylocaine and 1% dextrose was
followed 4% paraformadehyde in 0.1 M phosphate buffer solution
(PBS) (both at 37 degrees Celsius). The brains were carefully
removed from the skull and postfixed for 1 hour in the same
fixative used in the perfusion. The brain was blocked and cut into
2 mm thick sections using an acrylic brain matrix (David Kopf;
Tujunga, CA) to facilitate reproducibility of sections. These thick
sections were then sectioned into 80 micron thick coronal sections
using a Vibratome (VT1000E, Leica Microsystems, Wetzlar,
Germany).
Tissue sections were incubated with monoclonal anti-a-syn
(1:250; BD Transduction Laboratories, San Diego, CA) and rabbit
anti-mGluR5 (1:250; Millipore, Temecula, CA) followed by
incubation with donkey anti-mouse Alexa Red (1:100, Molecular
Probes, Carlsbad, CA) and donkey anti-rabbit FITC (1:100,
Jackson Immunoresearch Laboratories, Inc., West Grove, PA,
USA) overnight at 4C. The immunolabeling procedure consisted
of the following steps: (1) 665 min rinses in 0.1 M PBS; (2) 1 hr
blocking step in PBS containing 3% normal donkey (NDS), 0.1%
Triton X-100, 1% fish gelatin, and 1% BSA; (3) 48 hr incubation
in primary antibodies diluted in working buffer (PBS, 1% NDS) at
20 degrees C; (4) 665 minute rinsed in working buffer; (5) 24 hr
incubation in working buffer containing donkey anti-mouse Alexa
Fluor 488 (Molecular Probes, Carlsbad, CA) and donkey anti-
rabbit RRX (Jackson Immunoresearch Laboratories, Inc., West
Grove, PA, USA). (6) 6610 min rinses in working buffer; (7)
3610 min rinses in PBS; (8) the sections were free floated onto
slides and coverslipped using ProLong mounting media (Invitro-
gen Molecular Probes, Carlsbad, CA) with DAPI nuclear stain.
Controls for the mGluR5 antibody experiments included both
preabsorption with the control peptide (Chemicon,Temecula,
CA), as well as primary omission studies, which both revealed a
lack of non-specific staining (data not shown). Controls for other
antibodies used were performed via omission of primary
antibodies, and revealed no non-specific staining (data not shown).
All steps were conducted at 4uC, on wet ice and with ice-cold
solutions.
Acquisition of large-scale mosaic survey images
The wide-field mosaic image data sets were acquired with the
multiphoton scanning system described previously [57,58] and
these were used to survey brain regions for further targeted
imaging and analyses. For these purpose, sections double labeled
with antibodies against mGluR5 and a-syn as described above
were used. Representative large scale images were acquired using
a customized video-rate multiphoton microscope [59] equipped
with a custom automated high precision motorized stage (Applied
Precision LLC, Issaquah, WA), which allows for the automatic
acquisition of ultra-large field image mosaics in 2 and 3
dimensions [57,58]. A Nikon Plan Apo TIRF (6061.45) oil
immersion objective was used. These mosaic images are acquired
by rastering the specimen along the X, Y, and Z axes, introducing
a prescribed amount of overlap between acquired images (in this
case 10%) to aid alignment. Unprocessed image data acquired on
the high-speed multiphoton microscope is subsequently stored as a
single stack of images. The image stack is analyzed using the
JAVA-based ImageJ, a freely available software package, using
plugins developed at NCMIR for processing, aligning, and
assembling these massive datasets. Briefly, each file is separated
into three separate.tiff stacks, one for each channel. Each tile of the
image mosaic is normalized to eliminate shading gradients,
followed by the automatic alignment of individual tiles to form a
full size mosaic image of the data for each channel. A ‘‘globally
optimized,’’ normalized cross-correlation algorithm is used to
achieve sub-pixel alignment accuracy. The assembled mosaics are
then combined into one full-scale color image. For 3D imaging,
the process is repeated for each wide field image plane in Z. The
large-scale images were used to identify regions of interest for
confocal imaging studies.
Statistical analyses
One-way ANOVAs were performed for water maze and pole
test data using the Statview statistical package (version 5.0.1, Cary,
NC). Behavioral and image data were graphed using SigmaPlot
9.0 (Systat Software Inc., Richmond, CA). All data are presented
as the mean group value 6 the standard error of the mean. The
criterion for significance was set at p,0.05.
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Regionally selective increases in the levels of mGluR5 in
DLB and PD cases
Given the abundant expression of mGluR5 in brain regions
involved in AD and PD such as the frontal cortex, limbic system,
and caudoputamen [37], it has been proposed that alterations in
mGluR5 may be involved in the pathogenesis of AD [32] and PD
[33,34,35,36]. Nonetheless the relative levels of mGluR5 expres-
sion and alterations in DLB or PD have not been studied. For this
purpose, patterns of distribution for mGluR5 and the downstream
regulators were evaluated by immunocytochemistry and immu-
noblot analysis.
mGluR5 immunoreactivity was associated with pyramidal
neurons in layers 2–3 of the frontal cortex (Figure 1), in pyramidal
neurons in the CA3 region of the hippocampus and in mid-spiny
neurons in the caudo-putamen (Figure S1). Compared to control
cases, in DLB there was a significant increase in the levels of
mGluR5 immunoreactivity in neurons in the frontal cortex
(Figure 1A, B, D), hippocampus (Figure S1, A, B, D) and caudo-
putamen region (Figure S1E, F, analyzed in H) Compared to
controls, in the PD cases, levels of mGluR5 were increased in the
caudo-putamen (Figure S1E, G, H). However levels in the frontal
cortex and hippocampus were comparable to controls (frontal
cortex, Figure 1A, C, D; hippocampus, Figure S1A, C, D). Beta-
arrestin is a downstream regulator of mGluR5 recycling. Group I
mGluRs undergo rapid internalization after agonist exposure, this
internalization is strongly inhibited by the expression of both beta-
arrestin and dynamin dominant-negative mutants [60,61,62].
Similar to mGluR5, beta-arrestin was associated with pyramidal
neurons in layers 2–3 of the frontal cortex (Figure 1). Compared to
controls, beta-arrestin immunoreactivity was increased in the DLB
cases in the frontal cortex (Figure 1E, F, H). Compared to controls,
PD cases displayed no differences in beta-arrestin immunoreac-
tivity in the frontal cortex (Figure 1E, G, H). As expected,
compared to control cases, neocortical alpha-syn levels were much
higher in DLB and were associated with LBs in these cases as
opposed to the neuritic, punctate staining observed in the controls
(Figure 1I, J, L). There was no significant difference in neocortical
alpha-syn immunoreactivity in the PD cases compared to controls
(Figure 1I, K, L).
By immunoblot analysis, mGluR5 was identified in the
membrane fractions from athe frontal cortex, hippocampus and
caudate of controls, DLB and PD cases as a double band with an
Figure 1. Immunohistochemical analysis of mGluR5, beta-arrestin and alpha-syn in the frontal cortex of Control, DLB and PD cases.
(A, B, C) Representative bright field microscopy images of mGluR5 immunoreactivity in the frontal cortex of control, DLB and PD cases respectively.
(D) Analysis of mGluR5 immunoreactivity in the frontal cortex of control, DLB and PD cases. (E, F, G) Representative bright field microscopy images of
beta-arrestin immunoreactivity in the frontal cortex of control, DLB and PD cases respectively. (H) Analysis of beta-arrestin immunoreactivity in the
frontal cortex of control, DLB and PD cases. (I, J, K) Representative bright field microscopy images of alpha-syn immunoreactivity in the frontal cortex
of control, DLB and PD cases respectively. (L) Analysis of alpha-syn immunoreactivity in the frontal cortex control, DLB and PD cases. Scale bar
=30mM. * Indicates a significant difference between DLB or PD cases compared to control cases (p,0.05, one-way ANOVA and post hoc Fisher). #
Indicates a significant difference between DLB and PD cases (p,0.05, one-way ANOVA and post hoc Fisher) (n=8 cases per group).
doi:10.1371/journal.pone.0014020.g001
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controls, in the DLB cases, there was a significant increase in
mGluR5 levels in the membrane fractions from the frontal cortex
(Figure 2A, B), hippocampus (Figure 2C, D) and caudo-putamen
(Figure 2E, F). In PD cases, there was an increase in the levels of
mGluR5 in the membrane fraction of the caudo-putamen
(Figure 2E, F), but levels in the frontal cortex and hippocampus
were comparable to controls (Figure 2A–D). No mGluR5 was
detected in the cytosolic fractions. In a subset of the PD cases there
appeared to be an inverse relationship between monomeric alpha-
syn and mGluR5 levels in the membrane fraction from the frontal
cortex. This might be driven by the increased oligomerization of
alpha-syn in these cases, which might correlate with the increase of
mGluR5. Beta-arrestin was identified as a double band both in the
membrane (Figure 2A, C and E) and cytosolic (Figure 2G, I, K)
fractions with an approximate MW of 50 kDa. Compared to
controls, in the DLB cases, there was a significant increase in beta-
arrestin levels in the membrane fractions from frontal cortex
(Figure 2A, B), hippocampus (Figure 2C, D) and caudo-putamen
(Figure 2E, F). In PD cases, compared to controls, there was an
increase in the levels of beta-arrestin in the membrane fractions
from the hippocampus (Figure 2C, D) and caudo-putamen
(Figure 2E, F), but levels in the frontal cortex were comparable
to controls (Figure 2A, B). In the cytoplasmic fractions from the
frontal cortex beta-arrestin levels were reduced in both DLB and
PD cases compared to controls (Figure 2G, H). In cytoplasmic
fractions from the hippocampus, beta-arrestin levels were
increased in both DLB and PD cases compared to controls
(Figure 2I, J). In cytoplasmic fractions from the caudo-putamen
region beta-arrestin levels, in comparison to controls, were
unchanged in DLB, but higher in the PD cases (Figure 2K, L).
Levels of mGluR5 immunolabeling are elevated in the
brains of a-syn transgenic mice
Two different lines of tg mice were used, the first express alpha-
syn under the PDGF promoter which favors alpha-syn accumu-
lation in the frontal cortex and limbic system with a distributions
similar to DLB. The second express alpha-syn under the mThy-1
promoter, which results in greater accumulation of alpha-syn in
subcortical nuclei including the basal ganglia and midbrain,
analogous to PD. In both non-tg and tg mice lines, mGluR5
immunoreactivity was associated with pyramidal neurons in layers
2–3 of the frontal cortex (Figure 3A–C), in pyramidal neurons in
the CA3 region of the hippocampus (Figure S2A–C) and mid-
spiny neurons in the caudo-putamen (Figure S2E–G). Compared
to non-tg mice, in PDGF-alpha-syn tg mice there was a significant
increase in the levels of mGluR5 immunoreactivity in neurons in
the frontal cortex (Figure 3A, B, D), hippocampus (Figure S2A, B,
D) and caudo-putamen (Figure S2E, F, H). In the mThy1-alpha-
syn tg mice levels of mGluR5 immunoreactivity were similarly
increased in the frontal cortex (Figure 3A, C, D), hippocampus
(Figure S2A, C, D) and caudo-putamen (Figure S2E, G, H). In the
control non-tg mice mild levels of beta-arrestin immunoreactivity
were detected in pyramidal neurons in layers 2–3 and 5 of the
frontal cortex (Figure 3E). Levels of beta-arrestin immunoreactiv-
ity were increased in the frontal cortex of PDGF- and mThy1-
alpha-syn tg mice, compared to non-tg mice (Figure 3E–H).
By immunoblot analysis, mGluR5 was detected in the
membrane (Figure 4A) and cytosolic (Figure 4B) fractions as a
doublet with an estimated MW of 132 kDa. Consistent with the
immunocytochemical studies, levels of mGluR5 in the frontal
cortex were elevated in the membrane fractions of the alpha-syn tg
mice compared to non-tg controls (Figure 4A, C). Beta-arrestin
Figure 2. mGluR5, beta-arrestin and alpha-syn expression in frontal cortex, hippocampus and caudate of Control, DLB and PD
cases. (A) Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the membrane fraction of the frontal cortex from
control, DLB and PD cases. (B) Analysis of mGluR5 and beta-arrestin levels in the membrane fraction of the frontal cortex. (C) Representative
immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the membrane fraction of the hippocampus from control, DLB and PD cases.
(D) Analysis of mGluR5 and beta-arrestin levels in the membrane fraction of the hippocampus. (E) Representative immunoblot of mGluR5, beta-
arrestin and alpha-syn expression levels in the membrane fraction of the caudate from control, DLB and PD cases. (F) Analysis of mGluR5 and beta-
arrestin levels in the membrane fraction of the caudate. (G) Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in
the cytosolic fraction of the frontal cortex from control, DLB and PD cases. (H) Analysis of mGluR5 and beta-arrestin levels in the cytosolic fraction of
the frontal cortex. (I) Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the cytosolic fraction of the
hippocampus from control, DLB and PD cases. (J) Analysis of mGluR5 and beta-arrestin levels in the cytosolic fraction of the hippocampus. (K)
Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the cytosolic fraction of the caudate from control, DLB and
PD cases. (L) Analysis of mGluR5 and beta-arrestin levels in the cytosolic fraction of the caudate. * Indicates a significant difference between DLB or
PD cases compared to control cases (p,0.05, one-way ANOVA and post hoc Fisher). # Indicates a significant difference between DLB and PD cases
(p,0.05, one-way ANOVA and post hoc Fisher).
doi:10.1371/journal.pone.0014020.g002
mGluR5 in A-Synucleinopathy
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e14020was detected as a single band at 50 kDa in both the cytosolic and
membrane fractions. Compared to non-tg controls, in the PDGF-
and mThy1-alpha-syn tg mice the levels of beta-arrestin
immunoreactivity were increased the neocotex in both the
membrane (Figure 4A, C) and cytoplasmic (Figure 4B, D)
fractions.
mGluR5 interacts with a-syn in the brains of transgenic
animals
In order to identify whether the alterations in mGluR5 protein
levels were related to transcription changes at the mRNA level,
qPCR analysis was conducted. By qPCR, levels of mRNA were
comparable between DLB, PD and control cases (Figure S3A)
non-tg and PDGF- and mThy1-alpha-syn tg mice (Figure S3B),
suggesting that transcriptional events are not involved and that
the interaction between alpha-syn and mGluR5 occurs post-
transcription/post-translationally. Since, mGluR5 alterations by
immunoblot were primarily detected in the membrane rather than
cytosolic fractions and were accompanied by increased expression
of beta-arrestin suggesting that mGluR5 localization might be
altered by alpha-syn. Immunohistochemical double labeling with
antibodies against alpha-syn and mGluR5 showed a small degree
of alpha-syn co-localization with mGluR5 within the frontal cortex
of controls (Figure 5A-C) however the degree of co-localization
was greatly increased in the DLB (Figure 5D–F) and PD
(Figure 5G–I) cases. Consistent with the human cases, non-tg
mice showed a small degree of alpha-syn co-localization with
mGluR5 within pyramidal neurons in the frontal cortex of
(Figure 5J–L) however the degree of co-localization was greatly
increased in the PDGF-alpha-syn tg (Figure 5M–O) and mThy1-
alpha-syn tg (Figure 5P–R) mice.
In order to examine whether mGluR5 and alpha-syn interact
(directly or indirectly) co-immunoprecipitation (co-IP) studies were
conducted. When samples from the mouse brains of non-tg,
Figure 3. Immunohistochemical Analysis of mGluR5, beta-arrestin and alpha-syn in the frontal cortex of alpha-syn transgenic mice.
(A, B, C) Representative bright field microscopy images of mGluR5 immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-
alpha-syn tg mice, respectively. (D) Analysis of mGluR5 immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg
mice. (E, F, G) Representative bright field microscopy images of beta-arrestin immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and
mThy1-alpha-syn tg mice, respectively. (H) Analysis of beta-arrestin immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-
alpha-syn tg mice. (I, J, K) Representative bright field microscopy images of alpha-syn immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-
syn and mThy1-alpha-syn tg mice, respectively. (L) Analysis of alpha-syn immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and
mThy1-alpha-syn tg mice. Scale bar =30 mM. * Indicates a significant difference between alpha-syn tg mice compared to non-tg controls (p,0.05,
one-way ANOVA and post hoc Fisher) (n=8 cases per group).
doi:10.1371/journal.pone.0014020.g003
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precipitated with an antibody against mGluR5 and then analyzed
by immunoblot with an antibody against alpha-syn, the strongest
interaction was observed in the alpha-syn tg mice when compared
to non-tg controls (Figure 5S). No interacting bands were detected
in control experiments with samples immunoprecipitated with a
non-immune IgG or when the tissue sample was excluded.
Similarly when the reverse IP was performed, by immunoprecip-
itating with an antibody against alpha-syn and then analyzing by
immunoblot with an antibody against mGluR5, the strongest
interaction was again observed in the alpha-syn tg mice when
compared to non-tg controls (Figure 5T). No interacting bands
were detected in control experiments with samples immunopre-
cipitated with a non-immune IgG. To further validate the IP,
samples immunoprecipitated with the antibody against alpha-syn
were analyzed with an antibody against alpha-syn. This study
confirmed that in the samples from the alpha-syn tg mice higher
levels of alpha-syn immunoreactivity were detected than in the
non-tg mice (data not shown).
Wide field mosaic analysis of alpha-syn and mGluR5
distribution in alpha-syn transgenic mice
Wide field mosaic imaging was conducted to examine in a more
comprehensive manner the relationship between the distribution
of alpha-syn and mGluR5 immunolabeling in several brain
regions associated with rodent spatial memory and motor
functions. (Figure S4). Patterns of alpha-syn and mGluR5
immunolabeling were examined within the motor cortex, piriform
cortex, four sub-regions of striatum, three regions within the
hippocampal formation, and the substantia nigra. Alpha-syn
immunolabeling in non-tg samples was punctate in nature, and no
labeled cell bodies or neurites were observed in any samples. In
Figure 4. mGluR5, beta-arrestin and alpha-syn expression in frontal cortex of alpha-syn transgenic mice. (A) Representative
immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the membrane fraction of the frontal cortex from non-tg, PDGF-alpha-syn
and mThy1-alpha-syn tg mice. (B) Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the cytoplasmic fraction of
the frontal cortex from non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice. (C) Analysis of mGluR5 and beta-arrestin levels in the membrane
fraction of the frontal cortex. (D) Analysis of mGluR5 and beta-arrestin levels in the cytoplasmic fraction of the frontal cortex. * Indicates a significant
difference between alpha-syn tg mice and non-tg controls p,0.05, one-way ANOVA and post hoc Fisher). # Indicates a significant difference
between PDGF-alpha-syn and mThy1-alpha-syn tg mice (p,0.05, one-way ANOVA and post hoc Fisher)(n=8 mice per group).
doi:10.1371/journal.pone.0014020.g004
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increased, more diffuse in nature, and immunopositive cell bodies,
dendrites and other elements in the neuropil were observed in
many regions. In comparison, increased mGluR5 immunolabeling
was noted in nearly identical regions. The regional statistics are
provided in Table 2. Within the motor cortex (Figure S4B) an
increase in alpha-syn was noted in tg versus non-tg samples.
The mGluR5 labeling was diffuse in nature and included
immunopositive cell bodies present within the inner granular cell
layer. In non-tg samples we observed apparent axonal mGluR5
immunolabeling through the cortical layers presumably on
pyramidal cell axons. This pattern was also seen in the tg samples,
with a noticeable increase in the amount of staining, as well as an
extension of staining to varicosities along the axonal projections
through the outer granular layer. Alpha-syn immunolabeling
within tg piriform cortex (Figure S4B, C) was also more diffuse,
with immunopositive cell bodies and neurites present within the
cell body layers II and III. mGluR5 immunolabeling within the
piriform cortex of non-tg animals consisted of punctate staining
throughout the cell body layer. The levels were increased in tg
samples and also included increased axonal staining through the
piriform cortical cell body layers II and III. In contrast with the
immunostaining patterns observed within the aforementioned
cortical regions, the pattern of alpha-syn immunolabeling within tg
striatal regions (dorsomedial, dorsolateral, ventromedial and
ventrolateral) was punctate, and synaptic like in nature. No
immunopositive cell bodies or neurites were observed in any
striatal region (Figure S4B, D). Striatal mGluR5 immunolabeling
in tg samples was increased within the neuropil, and also included
perineuronal staining not observed in the non-tg. Sparse, small,
punctate alpha-syn immunolabeling was found in the substantia
nigra pars compacta (SNc) in non-tg samples. SNc immunolabel-
ing was increased in tg samples, with the addition of tyrosine
hydroxylase-like labeled projections innervating the substantia
nigra pars reticulata (Figure S4B). mGluR5 immunolabeling was
increased in the SNc and consisted of labeled fibers and neurites,
in a pattern similar to TH immunoreactivity.
Figure 5. Co-immunoprecipitation and co-localization of alpha-syn and mGluR5. (A, D, G) Representative confocal images of alpha-syn
immunolabeling in the frontal cortex of control, DLB and PD cases, respectively. (B, E, H) Representative confocal images of mGluR5 immunolabeling
in the frontal cortex of control, DLB and PD cases, respectively. (C, F, I) Co-localization of alpha-syn and mGluR5 immunoreactivity in the frontal cortex
of control, DLB and PD cases, respectively. (J, M, P) Representative confocal images of alpha-syn immunolabeling in the frontal cortex of non-tg,
PDGF-alpha-syn tg and mThy1-alpha-syn tg mice, respectively. (K, N, Q) Representative confocal images of mGluR5 immunolabeling in the frontal
cortex of non-tg, PDGF-alpha-syn tg and mThy1-alpha-syn tg mice, respectively. (L, O, R) Co-localization of alpha-syn and mGluR5 immunoreactivity in
the frontal cortex of non-tg, PDGF-alpha-syn tg and mThy1-alpha-syn tg mice, respectively. (S) Representative immunoblot of the co-
immunoprecipitation of mGluR5 and alpha-syn using the anti-mGluR5 antibody for the pull-down and the alpha-syn antibody for the detection. (T)
Representative immunoblot of the co-immunoprecipitation of mGluR5 and alpha-syn using the alpha-syn antibody for the pull-down and the anti-
mGluR5 antibody for the detection. Scale bar =20 mM.
doi:10.1371/journal.pone.0014020.g005
Table 2. Regional statistics and percentages for a-syn and
mGluR5 immunolabeling for data presented in Figure S4.
Mouse CNS
region alpha-syn Immunolabeling mGluR5 Immunolabeling
Motor Cortex +95.7%
p,0.05, F(1,11)=8.99
+120.8%
p,0.01, F(1,11)=20.64
Piriform Cortex +5.6%
n.s., F(1,9)=0.28
+53.13%
P,0.01, F(1,9)=51.59
Dorsomedial
Striatum
+275.6%
p,0.01, F(1,14)=17.60
+159.6%
p,0.01, F(1,14)=55.63
Dorsolateral
Striatum
+199.6%
p,0.01, F(1,14)=17.22
+150.6%
p,0.01, F(1,14)=100.54
Ventromedial
Striatum
+42.7%
p,0.05, F(1,14)=8.57
+62.3%
p,0.05, F(1,14)=4.77
Ventrolateral
Striatum
+112.2%
p,0.01, F(1,14)=8.04
+98.5%
p,0.01, F(1,14)=38.27
Substantia Nigra +55.5%
p,0.01, F(1,11)=7.41
+59.26%
p,0.05, F(1,11)=7.41
CA1 region +178.5
p,0.01, F(1,10)=103.95
+51.52%
n.s., F(1,10)=4.57
CA3 region +97.8%
p,0.05, F(1,7)=8.97
+259.3%
p,0.01, F(1,7)=42.53
Dentate Gyrus +51.4%
p,0.05, F(1,17)=6.70
+80.7%
p,0.01, F(1,17)=32.59
doi:10.1371/journal.pone.0014020.t002
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mGluR5 immunolabeling within CA1, CA3 and dentate gyrus.
Within the CA1 field of non-tg samples, alpha-syn immunolabel-
ing within the neuropil was largely confined to the area
immediately surrounding the pyramidal cell layer. Within the
pyramidal cell layer of CA1, alpha-syn immunolabeling was
present on axonal projections and surrounding cell bodies.
mGluR5 labeling within the CA1 largely followed the pattern of
alpha-syn immunoreactivity. Axonal mGluR5 staining was also
evident through the extent of the pyramidal cell layer with labeled
axonal projections towards the stratum radiatum (Figure S4B).
Within the CA3 region of non-tg samples, punctate alpha-syn
immunolabeling was largely confined to the area adjacent to the
stratum lucidum. An expansion of alpha-syn immunoreactivity
was seen in tg samples with an increase in staining within the
neuropil, and including many immunopositive cell bodies within
the stratum lucidum (Figure S4B). In non-tg samples, the pattern
of larger punctate mGluR5 immunolabeling corresponded to the
distribution of alpha-syn immunoreactivity. Like alpha-syn
immunoreactivity in tg animals, mGluR5 immunolabeling was
increased in tg mice throughout the neuropil and surrounded cell
bodies within the stratum lucidum.
Alpha-syn immunolabeling was sparse within all sub-regions of
non-tg dentate gyrus, and was substantially increased within
molecular layers, hilus and supra- and infrapyramidal blades of the
dentate gyrus (Figure S4B). This included punctate labeling in the
neuropil surrounding cell bodies and cytoplasmic labeling of cells
within the hilus. mGluR5 labeling of non-tg dentate gyrus
included labeling of collateral varicosities within the hilus, diffuse
labeling of the neuropil in the molecular layers, and minimal
axonal-like labeling through cell body layers of the suprapyramidal
and infrapyramidal blades. The intensity of mGluR5 labeling was
increased in tg samples and included labeling of intracytoplasmic
regions of large neuronal cell bodies, with an approximate shape
and size appropriate for interneurons and main apical dendrites
within the hilus.
Increased mGluR5 signaling in DLB/PD and alpha-syn
transgenic mice
In order to investigate whether the increased mGluR5 level in
the DLB and PD cases and in the alpha-syn tg mice was associated
with a concomitant increase in the levels of downstream signaling
components, levels of total and phosphorylated ERK, Elk–1 and
CREB were examined in the cytoplasmic and membrane fractions
from the frontal cortex. In the membrane fraction ERK activation
(ratio of pERK/tERK) was increased in the DLB and PD cases in
comparison to the control cases (Figure 6A, E). Elk-1 activation
(ratio of pElk-1/tElk-1) was increased in the membrane fraction
from the DLB cases but not PD cases, when compared to controls.
(Figure 6A, G). CREB activation (ratio of pCREB/tCREB) was
increased in the nuclear fraction from the DLB and PD cases when
compared to controls (Figure 6C, I), In the cytoplasmic fraction,
both DLB and PD cases displayed increased ERK activation (ratio
pERK/totalERK) compared to control cases (Figure 6B, F). No
significant differences in Ekl-1 activation were noted between DLB
or PD cases and controls (Figure 6B, H). CREB activation was
decreased in the soluble fraction from both DLB and PD when
compared to control cases (Figure 6D, J). A similar immunoblot to
investigate downstream signaling components was conducted on
the membrane, cytosolic and nuclear fractions from the frontal
cortex of non-tg and alpha-syn tg mice (Figure 7).
The ERK activation was increased in the mThy-1-alpha-syn tg
mice in both the membrane (Figure 7A, E) and cytoplasmic
(Figure 7B, F) fractions in comparison to non-tg controls, however
it did not differ between PDGF-alpha-syn tg mice and non-tg
controls on either fraction (Figure 7A, B, E, F). The membrane
fraction both the PDGF-alpha-syn and mThy1-alpha-syn tg mice
displayed increased levels of Elk-1 activation in comparison to
non-tg controls (Figure 7A, G). No Elk-1 activation was detected in
the cytoplasmic fraction (Figure 7B, H). CREB activation was
increased in the PDGF-alpha-syn and mThy1-alpha-syn tg mice in
the nuclear fraction compared to non-tg controls (Figure 7C, I),
however in the soluble fraction CREB activation was only
increased in the mThy1-alpha-syn tg mice when compared to
non-tg controls (Figure 7D, J).
Motor deficits in the pole test apparatus in alpha-syn
transgenic mice are ameliorated by the mGluR5 inhibitor
MPEP
In the tg mice there is considerable accumulation of alpha-syn
in the caudo-putamen region that is accompanied by motor
deficits in the pole test. Since it is possible that increased
expression of mGluR5 in mid-spine neurons as shown here might
play a role in the motor deficits, non-tg and alpha-syn tg mice were
treated with the mGluR5 antagonist MPEP and tested in the pole
test. This behavioral test requires the subjects to grip and traverse
the pole requiring motor strength and coordination [54,63]. The
stringent test parameters help to ensure that tg deficits are not
obscured by compensatory responses (e.g. incomplete turns prior to
descending the pole apparatus). Compared with non-tg mice,
alpha-syn tg mice were impaired in ability to negotiate the pole
apparatus as evidenced by a significant longer T-Turn time
(Baseline, Figure 8A).
To assess whether mGluR5 antagonism could ameliorate the
pole test behavioral deficit observed in the tg animals, mice were
treated with the mGluR5 antagonist MPEP. Following treatment
with MPEP T-Turn was comparable between the non-tg and
alpha-syn tg mice (MPEP Treatment, Figure 8A). Analysis of the
difference between the first and second test days revealed an
improvement in T-Turn times of the alpha-syn tg mice as
indicated by significant improvement in the success ratio from the
first test to second test session (F(1,6)=6.40; p=0.0447). When the
mice were tested a day after the MPEP treatment (Re-test, no
treatment, Figure 8A), once more alpha-syn tg mice displayed
impaired performance in the pole test when compared to the non-
tg controls (F(1,6)=18.498; p=0.0051).
The spatial memory deficits in alpha-syn transgenic mice
are ameliorated by the mGluR5 inhibitor MPEP
Though motor deficits are more often highlighted, cognitive
deficits associated with alpha-syn accumulation in the limbic
system have also been reported in patients with Parkinson’s disease
dementia and dementia with LB’s [56]. These alterations might be
associated with the increased expression of mGluR5 in the frontal
cortex and hippocampus of the alpha-syn tg mice. To investigate
this possibility, mice were tested in the water maze and treated
with the mGluR5 antagonist MPEP. During the training period of
the test, repeated measures ANOVA revealed no significant
differences among the groups path length (F(1,12)=2.294,
p=0.1557 and F(1,6)=0.500, p=0.8060). During the spatial
learning period of the test with the platform submerged, vehicle
treated alpha-syn tg mice displayed performance deficits when
compared to the vehicle treated non-tg controls (Figure 8B). In
contrast, MPEP treatment improved the behavioral performance
of the alpha-syn tg compared to the vehicle treated alpha-syn tg
mice (Figure 8C). The MPEP treated alpha-syn tg mice
performance was similar to the non-tg controls. In the last day
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significant main effect of the genotype on entrances and passes into
target zone (F(1,12)=6.649, p=0.0242). In contrast, alpha-syn tg
mice treated with MPEP exhibited a similar number of entrances
and passes into target zone when compared to the non-tg controls.
MPEP treatment had no effect on the performance of the non-tg
mice (Figure 8D).
A subsequent trial in which the platform was visible, confirmed
that both groups were able to locate the platform via visual
sighting. These results indicate that the deficit in ability to locate
the correct zone, seen in the alpha-syn tg mice, is not attributable
to a visual or gross motor deficit, but is instead likely to be a
consequence of a memory or spatial navigation defect.
Discussion
Excitoxicity has been proposed to play a role in the mechanisms
of neurodegeneration in DLB and PD. The present study showed
that alterations in the levels of mGluR5 in selected brain regions in
patients with DLB or PD and in alpha-syn transgenic mice might
be involved. Specifically, mGluR5 was increased in the frontal
cortex, hippocampus and caudate in DLB in and in the caudate in
PD, these areas correspond closely with areas displaying increased
alpha-syn accumulation. The results of this study are consistent
with previous studies that have shown increased expression or
activation of glutamate receptors in the acute neurotoxicity rodent
[43] and primate [64] models of PD and in other neurodegen-
erative disorders with protein accumulation such as Amyotrophic
lateral sclerosis (mGluR5; [65]), Down’s syndrome (mGluR5;
[66]), and AD (mGluR2/3; [32,67,68,69]). However, our study is
the first to document alterations in mGluR5 in human DLB and
PD cases and in alpha-syn tg mice.
The important of metabotropic glutamate receptors, particu-
larly mGluR5, in neurodegenerative disorders is underlined by
recent work suggesting that excitotoxicity mediated by metabo-
tropic receptors may be a key mechanism underlying neurode-
generation [70,71] and by recent experimental therapies based in
the development of mGluR5 antagonists [71,72,73,74]. Consistent
with this proposed role of mGluR5 in excitotoxicity and the
potential therapeutic use of mGluR5 antagonists we show that
when the alpha-syn tg mice were treated with the mGluR5
antagonist MPEP their motor and learning/memory deficits were
ameliorated. This is in agreement with previous studies showing
that mGluR5 inhibitors reduce the motor alterations in rodent
models challenged with MPTP or 6-OH DOPA [75,76,77,78] and
recent studies in primates showing that MPEP and another
mGluR5 antagonist such as MTEP (3-((2-Methyl-4-thiazolyl)ethy-
nyl)pyridine) has beneficial anti-dyskinetic effects in L-Dopa-
treated MPTP monkeys [79,80]. Moreover, co-administration of
adenosine 2A and mGluR5 antagonists reverses the behavioral
Figure 6. Immunoblot analysis of ERK, Elk-1 and CREB activity in Control, DLB and PD cases. (A) Representative immunoblot of phospho-
ERK (pERK), total ERK (tERK) phospho-ELK-1 (pELK-1) and total ELK-1 (tELK-1) expression levels in the membrane fraction from the frontal cortex of
control, DLB and PD cases. (B) Representative immunoblot of pERK, tERK, pELK-1 and tELK-1 expression in the cytoplasmic fraction from the frontal
cortex of control, DLB and PD cases. (C) Analysis of ERK activity (pERK/tERK ratio) in the membrane fraction. (D) Analysis of ERK activity (pERK/tERK
ratio) in the cytosolic fraction. (E) Analysis of Elk-1 activity (pElk-1/tElk-1 ratio) in the membrane fraction. (F) Analysis of Elk-1 activity (pElk-1/tElk-1
ratio) in the cytosolic fraction. (G) Representative immunoblot of phospho-CREB (pCREB) and total CREB (tCREB) in the nuclear fraction from the
frontal cortex of control, DLB and PD cases. (H) Representative immunoblot of pCREB and tCREB in the soluble fraction from the frontal cortex of
control, DLB and PD cases. (I) Analysis of CREB activity in the nuclear fraction. (J) Analysis of CREB activity in the soluble fraction. * Indicates a
significant difference between DLB or PD cases compared to control cases. (p,0.05, one-way ANOVA and post hoc Fisher) (n=8 cases per group).
doi:10.1371/journal.pone.0014020.g006
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the effects at reducing motor alterations, MPEP has been shown to
reduce the visuo-spatial discrimination deficit induced by bilateral
dopamine lesion of the striatum [81]. This same treatment
increased contralateral turning induced by L-DOPA in mice
bearing unilateral 6-OHDA lesion suggesting that mGluR5
blockade may also have beneficial effects on cognitive deficits
induced by dopamine depletion [81]. Therefore, both neurotoxic
and transgenic models of parkinsonism support the possibility that
antagonism of mGluR5 might be potentially beneficial in the
treatment of DLB and PD patients.
mGluR5 has attracted considerable interest due to its abundant
expression in the frontal cortex, limbic system, and caudo-putamen
[37]—brain regions selectively affected in PD. The vulnerability of
selected neuronal populations in PD and DLB patients has been
linked to glutamate-mediated excitotoxicity [82]. Consistent with
this, the double labeling and mosaic analysis showed that there was
some regional specificity to the increased levels of mGluR5 that
corresponded to the areas of greater a-syn accumulation and
neurodegeneration. For example, in the DLB cases mGluR5 was
elevated in the frontal cortex, limbic system and putamen, while in
the PD cases the increase was more prominent in the putamen. In
the PDGF-alpha-syn tg mice mGluR5 increases were more
prominent in the frontal cortex and limbic system while in the
mThy1-alpha-syn tg mice mGluR5 was also elevated in the
striatum. Of the affected areas mGluR5 was found in pyramidal
neurons in the deeper layers of the frontal cortex, CA3 region of the
hippocampus and mid-spiny neurons in the striatum. These are all
neuronal populations and brain regions selectively affected in DLB
and PD patients [11,83,84,85] suggesting that mGluR5 might play
a role in the mechanisms of selective neuronal vulnerability in
disorders with alpha-syn accumulation.
Figure 7. Immunoblot Analysis of ERK, Elk-1 and CREB activity in alpha-syn transgenic mice. (A) Representative immunoblot of phospho-
ERK (pERK), total ERK (tERK) phospho-ELK-1 (pELK-1) and total ELK-1 (tELK-1) expression levels in the membrane fraction from the frontal cortex of
non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice. (B) Representative immunoblot of pERK, tERK, pELK-1 and tELK-1 expression in the
cytoplasmic fraction from the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice. (C) Analysis of ERK activity (pERK/tERK ratio) in
the membrane fraction. (D) Analysis of ERK activity (pERK/tERK ratio) in the cytosolic fraction. (E) Analysis of Elk-1 activity (pElk-1/tElk-1 ratio) in the
membrane fraction. (F) Analysis of Elk-1 activity (pElk- 1/tElk-1 ratio) in the cytosolic fraction. (G) Representative immunoblot of phospho- CREB
(pCREB) and total CREB (tCREB) in the nuclear fraction from the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice. (H)
Representative immunoblot of pCREB and tCREB in the soluble fraction from the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg
mice. (I) Analysis of CREB activity in the nuclear fraction. (J) Analysis of CREB activity in the soluble fraction. * Indicates a significant difference between
alpha-syn tg mice and non-tg controls p,0.05, one-way ANOVA and post hoc Fisher). # Indicates a significant difference between PDGF-alpha-syn
and mThy1-alpha-syn tg mice (p,0.05, one-way ANOVA and post hoc Fisher)(n=8 mice per group).
doi:10.1371/journal.pone.0014020.g007
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DLB, PD and tg models might lead to the increase mGluR5 is not
completely clear. However the alterations in mGluR5 are most
likely post-translational since levels of mGluR5 mRNA did not
differ between control and DLB or PD cases or between non-tg
and alpha-syn transgenic mice. Thus, it is possible that alpha-syn
interacts with mGluR5 to alter the distribution of these receptors
at the cell membrane of particular cell populations, which may
lead to an increase in mGluR5 activity and glutamate-mediated
excitotoxicity in specific brain regions. In support of this
interaction hypothesis we showed a greater degree of mGluR5
and alpha-syn co-immunoprecipitation in the alpha-syn tg mice
compared to non-tg mice and a greater accumulation of mGluR5
in the membrane fractions from DLB or PD cases and in alpha-
syn tg mice compared to control cases or non-tg mice. Moreover
the increase in mGluR5 was accompanied by an increase in beta-
arrestin, a protein involved in the internalization and recycling of
the receptor. Taken together, these results suggest that accumu-
lation of alpha-syn might alter mGluR5 localization at the cell
surface, allowing a greater proportion to remain membrane-
associated rather than being recycled.
If this is the case, then it is also possible that increased presence
of the receptor at the cell surface may lead to over activation of the
downstream mGluR5 signaling pathway. mGluR5 is a Group I
metabotropic glutamate receptor that couples with phospholipase
C (PLC) via Gq-like G-proteins. PLC activates protein kinase-C
(PKC) activation via diacylglycerol and PKC goes on to
phosphorylate and activate ERK, which activates ElK-1. PLC
additionally activates inositol 1,4,5-trisphosphate (IP3) resulting in
the release of calcium from intracellular stores such as the
endoplasmic reticulum. This calcium in turn activates a number of
calcium-responsive proteins such as those involved in the calcium/
calmodulin/calmodulin kinase (CaM kiinase) cascade including
CaMKinase I and IV which phosphorylate cyclic-AMP response
element-binding (CREB) and activate gene expression [86].
We demonstrate that the increased expression of mGluR5 in
DLB, PD and alpha-syn tg mice is accompanied by an increase
activation of down-stream signaling pathway components includ-
ing ERK, Elk-1 and CREB. Dysregulated calcium homeostasis has
been linked to a number of neurodegenerative diseases including
PD and AD [87] and as over activation of the mGluR5 signaling
pathway may also contribute to increases in intracellular calcium it
might play a role in mGluR5-mediated selective vulnerability.
In addition to the increased expression and over activation of
mGluR5, alpha-syn has been reported to interact with individual
components of the mGluR5 signaling pathway including ERK
and Elk-1 [88,89], this is supported by the detection of ERK, Elk-1
and alpha-syn in Lewy Body aggregates. Iwata and colleagues
have demonstrated that in vitro over expression of alpha-syn
reduces ERK-1/2 phosphorylation and activation of ERK-1/2
signaling, eventually resulting in cell death [90]. Therefore it is
possible that alpha-syn may modulate mGluR5 activity both
directly - by increasing cell surface concentrations of the receptor
itself, as evidenced by the concomitant increase in levels of beta-
arrestin that may serve to keep greater proportions of the receptor
at the cell surface rather than being recycled and indirectly - by
binding to the downstream signaling components of the mGluR5
pathway.
Taken together the results from study this support the notion
that alpha-syn may directly interact with mGluR5 resulting in its
over activation and suggest that this over activation may
contribute to excitotoxic cell death in selected neuronal popula-
Figure 8. Motor and learning/memory deficits in alpha-syn transgenic mice are ameliorated by MPEP administration. (A) Pole test
performance (T-Turn) of the non-tg and PDGF-alpha-syn tg mice, at baseline, following MPEP treatment and at re-test (no treatment). (B) Morris water
maze performance of vehicle-treated non-tg and PDGF-alpha-syn tg mice. (C) Morris water maze performance of MPEP- treated PDGF-alpha-syn tg
mice. (D) Morris water maze performance of MPEP-treated non-tg mice. * Indicates a significant difference between groups examined (p,0.05, one-
way ANOVA and post hoc Fisher) (n=8 per group).
doi:10.1371/journal.pone.0014020.g008
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highlight the potential therapeutic importance of mGluR5
antagonists in disorders characterized by alpha-syn accumulation.
Supporting Information
Figure S1 Hippocampal and caudate levels of mGluR5 in
Control, DLB and PD cases. (A–C) Representative images of
mGluR5 immunoreactivity in the CA2/3 of the hippocampus
from control, DLB and PD cases respectively, analyzed in (D). (E–
G) Representative images of mGluR5 immunoreactivity in the
caudate from control, DLB and PD cases respectively, analyzed in
(H). Scale bar =50 mM * Indicates a significant difference
between DLB or PD cases compared to control cases (p,0.05,
one-way ANOVA and post hoc Fisher). # Indicates a significant
difference between DLB and PD cases (p,0.05, one-way ANOVA
and post hoc Fisher) (n=8, case per group).
Found at: doi:10.1371/journal.pone.0014020.s001 (2.38 MB TIF)
Figure S2 Hippocampal and caudate levels of mGluR5 in
alpha-syn transgenic mice. (A–C) Representative images of
mGluR5 immunoreactivity in the CA2/3 of the hippocampus of
non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice respec-
tively, analyzed in (D). (E–G) Representative images of mGluR5
immunoreactivity in the caudate of non-tg, PDGF-alpha-syn and
mThy1-alpha-syn tg mice respectively, analyzed in (H). * Indicates
a significant difference between alpha-syn tg mice compared to
non-tg controls (p,0.05, one-way ANOVA and post hoc Fisher).
Found at: doi:10.1371/journal.pone.0014020.s002 (2.34 MB TIF)
Figure S3 mGluR5 mRNA levels in Control, DLB and PD cases
and alpha-syn transgenic mice. (A) Quantitative real-time PCR
(qPCR) analysis of mGluR5 mRNA levels in Control, DLB and
PD cases. (B) qPCR analysis of mGluR5 mRNA levels in non-tg,
PDGF-alpha-syn tg and mThy1-alpha-syn tg mice.
Found at: doi:10.1371/journal.pone.0014020.s003 (0.27 MB TIF)
Figure S4 High-resolution, large-scale maps of alpha-syn and
mGluR5 in alpha-syn transgenic mice. (A) Representative confocal
image depicting localization of alpha-syn (green) and mGluR5
(red) immunoreactivity in an alpha-syn tg mouse brain - inset at
higher magnification in the right panel. (B) Representative
confocal image depicting localization of alpha-syn and mGluR5
immunoreactivity in the motor cortex (mCtx), piriform cortex
(pCtx), CA1 region of hippocampus (CA1), CA3 region of
hippocampus, (CA3), dentate gyrus (DG), dorsomedial striatum,
(dmSTR) and substantia nigra (SN) in non-tg and alpha-syn tg
mice respectively. (C) Semi-quantitative analysis of mGluR5
immunoreactivity in the mCtx, pCtx, CA1, CA3, and DG of
non-tg and alpha-syn tg mice. (D) Semi-quantitative analysis of
mGluR5 immunoreactivity in the dmSTR, dorsolateral striatum
(dlSTR), ventromedial striatum (vmSTR), ventrolateral striatum
(vlSTR) and SN of non-tg and alpha-syn tg mice. Imaging
parameters were kept consistent within regions and data are
presented as mean pixel intensity 6 SEM. * Indicates a significant
difference between non-tg and alpha-syn tg mice (p,0.05, one-
way ANOVA and post hoc Fisher).
Found at: doi:10.1371/journal.pone.0014020.s004 (5.47 MB TIF)
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